E
Emily Shacter
Researcher at Center for Drug Evaluation and Research
Publications - 61
Citations - 10586
Emily Shacter is an academic researcher from Center for Drug Evaluation and Research. The author has contributed to research in topics: Apoptosis & Oxidative stress. The author has an hindex of 40, co-authored 61 publications receiving 9968 citations. Previous affiliations of Emily Shacter include National Institutes of Health & Food and Drug Administration.
Papers
More filters
Book ChapterDOI
Carbonyl assays for determination of oxidatively modified proteins
TL;DR: New methods for determination ofcarbonyl content are presented, which are based on the reaction of carbonyl groups with 2,4-dinitrophenylhydrazine to form a 2, 4-d Initrophenolhydrazone, which provide substantial improvements in both sensitivity and specificity.
Journal ArticleDOI
Pharmacologic ascorbic acid concentrations selectively kill cancer cells: Action as a pro-drug to deliver hydrogen peroxide to tissues
Qi Chen,Michael Graham Espey,Murali C. Krishna,James B. Mitchell,Christopher Corpe,Garry R. Buettner,Emily Shacter,Mark Levine +7 more
TL;DR: Human pharmacokinetics data indicate that ascorbate at concentrations achieved only by i.v. administration may be a pro-drug for formation of H(2)O(2), and that blood can be a delivery system of the pro- drug to tissues.
Journal Article
Chronic inflammation and cancer.
TL;DR: The contribution of reactive oxygen and nitrogen intermediates, prostaglandins, and inflammatory cytokines to carcinogenesis is discussed, which can lead to novel approaches to the prevention and treatment of cancer.
Journal ArticleDOI
Quantification and significance of protein oxidation in biological samples
TL;DR: This review will examine various aspects of protein oxidation, with emphasis on using proteins as markers of oxidative stress in biological samples, and monitor the degree of oxidative modification of therapeutic proteins manufactured for commercial use.
Journal ArticleDOI
Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo.
Qi Chen,Michael Graham Espey,Andrew Y. Sun,Je-Hyuk Lee,Murali C. Krishna,Emily Shacter,Peter L. Choyke,Chaya Pooput,Kenneth L. Kirk,Garry R. Buettner,Mark Levine +10 more
TL;DR: The data show that pharmacologic ascorbate is a prodrug for preferential steady-state formation of Asc•− and H2O2 in the extracellular space but not blood, which provides a foundation for pursuing pharmacological ascorBate as a prooxidant therapeutic agent in cancer and infections.